Odyssey Health Loses Exclusive Global Distribution Rights for BreastCheck Product

summarizeSummary

Odyssey Health, Inc. announced the immediate cancellation of its exclusive global sub-license agreement for the BreastCheck product due to a breach of contract by its partner, NeuRX Health, Inc.

check_boxKey Events

• Exclusive Sub-License Agreement Cancelled

  Odyssey Health received formal notice that its definitive agreement with NeuRX Health, Inc., for the exclusive global sub-license of the BreastCheck product, is immediately cancelled.

• Breach of Contract by Partner

  The cancellation stems from NeuRX Health's breach of its contractual obligations with Davion Healthcare Plc, specifically failing to obtain required approval before sublicensing BreastCheck to Odyssey.

• Reversal of Prior Announcement

  This event reverses the Master Technology and Sub-license Agreement that was announced as closed on April 21, 2026, removing a previously anticipated revenue stream.

• Impact on Financial Outlook

  The loss of this product agreement is a material negative event for Odyssey Health, especially given its recent 'going concern' warning, as it removes a significant potential source of future revenue.

auto_awesomeAnalysis

This filing announces the immediate cancellation of Odyssey Health's exclusive global sub-license agreement for the BreastCheck product. This is a significant setback, reversing a previously announced key partnership that was expected to drive future revenue. For a company already facing a 'going concern' warning, the loss of a material product agreement further complicates its ability to generate revenue and improve its financial position, potentially increasing the need for additional dilutive financing.